Pharmacokinetic-pharmacodynamic population modelling in paediatric anaesthesia and its clinical translation

被引:9
|
作者
Morse, James D. [1 ]
Hannam, Jacqueline [1 ]
Anderson, Brian J. [2 ]
机构
[1] Univ Auckland, Dept Pharmacol & Clin Pharmacol, Auckland, New Zealand
[2] Univ Auckland, Dept Anaesthesiol, Auckland, New Zealand
关键词
anaesthesia; children; modeling; pharmacodynamics; pharmacokinetics; INHALATION ANESTHESIA; CHILDREN; PROPOFOL; DEXMEDETOMIDINE; REMIFENTANIL; SIZE; PHARMACOLOGY; COMBINATION; CLEARANCE; ACETAMINOPHEN;
D O I
10.1097/ACO.0000000000000725
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Purpose of review Pharmacokinetic-pharmacodynamic (PKPD) population modelling has advanced adult anaesthesia. Current literature was reviewed to discern use of this analytic technique for benefit in the perioperative management of children. Recent findings Variability in drug response, selection of a dose that achieves a desired target concentration and optimizing sampling protocols for further studies are all facets of paediatric anaesthesia that have benefitted from modelling approaches. PKPD models have driven the maintenance dose rate in target-controlled infusion pumps used for total intravenous anaesthesia. Although many of the models used in these pumps were developed in adults, translation for paediatric use has followed, including subgroups, such as neonates and obese children. The use of drug effect measures (e.g. bispectral index) has improved the predictive performance of pharmacodynamic models. Simulation studies have facilitated an increase in safety by quantifying drug variability, and identifying where possible adverse drug events may occur. Summary Modelling and simulation continue to have an important role optimizing drug use during anaesthesia. Models incorporating influential covariates that better describe drug pharmacokinetics and pharmacodynamics improve anaesthetic treatments and safety in diverse populations and clarify drug role and impact. Their use developing paediatric clinical studies improves trial conduct, often with fewer subjects required for study.
引用
收藏
页码:353 / 362
页数:10
相关论文
共 50 条
  • [31] An Approach for Identifiability of Population Pharmacokinetic-Pharmacodynamic Models
    Shivva, V.
    Korell, J.
    Tucker, I. G.
    Duffull, S. B.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (06):
  • [32] Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel
    Bruno, R
    Vivier, N
    Veyrat-Follet, C
    Montay, G
    Rhodes, GR
    INVESTIGATIONAL NEW DRUGS, 2001, 19 (02) : 163 - 169
  • [33] POPULATION PHARMACOKINETIC-PHARMACODYNAMIC METHODOLOGY AND APPLICATIONS - A BIBLIOGRAPHY
    YUH, L
    BEAL, S
    DAVIDIAN, M
    HARRISON, F
    HESTER, A
    KOWALSKI, K
    VONESH, E
    WOLFINGER, R
    BIOMETRICS, 1994, 50 (02) : 566 - 575
  • [34] Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation
    Eleveld, D. J.
    Colin, P.
    Absalom, A. R.
    Struys, M. M. R. F.
    BRITISH JOURNAL OF ANAESTHESIA, 2018, 120 (05) : 942 - 959
  • [35] Pharmacokinetic-Pharmacodynamic Modelling of Posaconazole exposure for invasive aspergillosis
    Gastine, S.
    Hope, W.
    Hempel, G.
    Petraitis, V.
    Petraitiene, R.
    Walsh, T. J.
    Groll, A. H.
    MYCOSES, 2018, 61 : 32 - 33
  • [36] Pharmacokinetic-pharmacodynamic modelling for captopril in healthy anaesthetized piglets
    Pereira, CM
    Tam, YK
    Coe, JY
    Olley, PM
    CollinsNakai, RL
    BIOPHARMACEUTICS & DRUG DISPOSITION, 1996, 17 (05) : 365 - 372
  • [37] PRELIMINARY PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF THEOPHYLLINE AND ITS POSSIBLE CLINICAL IMPLICATIONS
    HEGER, RJ
    BRADBERRY, JC
    HOOVER, D
    VADIEI, K
    ODELL, D
    YOUNG, D
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1984, 18 (06): : 505 - 505
  • [38] Pharmacokinetic-pharmacodynamic modelling of intravenous buprenorphine in conscious horses
    Love, Emma J.
    Pelligand, Ludovic
    Taylor, Polly M.
    Murrell, Joanna C.
    Sear, John W.
    VETERINARY ANAESTHESIA AND ANALGESIA, 2015, 42 (01) : 17 - 29
  • [39] Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes
    Varlet-Marie, E
    Gaudard, A
    Audran, M
    Gomeni, R
    Bressolle, F
    INTERNATIONAL JOURNAL OF SPORTS MEDICINE, 2003, 24 (04) : 252 - 257
  • [40] Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats
    Cox, EH
    VanHemert, JGN
    Tukker, EJ
    Danhof, M
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1997, 38 (02) : 99 - 108